Ciprofloxacin-Resistant Salmonella enterica Serovar Kentucky in Canada
Michael R. Mulvey , David A. Boyd, Rita Finley, Ken Fakharuddin, Stacie Langner, Vanessa Allen, Lei Ang, Sadjia Bekal, Sameh El Bailey, David Haldane, Linda Hoang, Greg Horsman, Marie Louis, Lourens Robberts, and John Wylie
Author affiliations: Public Health Agency of Canada, Winnipeg, Manitoba, Canada (M. R. Mulvey, D. A. Boyd, K. Fakharuddin, S. Langner); Public Health Agency of Canada, Guelph, Ontario, Canada (R. Finley); Ontario Agency for Health Protection and Promotion, Toronto, Ontario, Canada (V. Allen); Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada (L. Ang); Institut National de Santé Publique du Quebec, Montreal, Quebec, Canada (S. Bekal); Saint John Regional Hospital, Saint John, New Brunswick, Canada (S. El Bailey); Provincial Public Health Laboratory Network of Nova Scotia, Halifax, Nova Scotia, Canada (D. Haldane); British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada (L. Hoang); Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada (G. Horsman); Alberta Provincial Laboratory for Public Health, Calgary, Alberta, Canada (M. Louis); Newfoundland Public Health Laboratory, St. John’s, Newfoundland, Canada (L. Robberts); Cadham Provincial Laboratory, Winnipeg, Manitoba (J. Wylie)
Figure 2. . Dendrograms of macrorestriction fragments of all (A) and ciprofloxacin-resistant (B) Salmonellaenterica serovar Kentucky isolates identified in Canada, 2003–2009. The dotted vertical line in panel A indicates a cutoff value of 80% similarity, and the box indicates ciprofloxacin-resistant isolates. Left end and Right end in panel B indicate PCR results for presence (Pos) or absence (Neg) of left and right junctions of Salmonella genomic island 1. PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; Ac, amoxicillin clavulanate; Am, ampicillin; Ch, chloramphenicol; Ci, ciprofloxacin; Ge, gentamicin; Na, nalidixic acid; St, streptomycin; Su, sulfisoxazole; Te, tetracycline; ST, sequence type; Tm, trimethoprim; PEI, Prince Edward Island. Letters in parentheses indicate drugs that had intermediate MICs.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.